Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial

Abstract Background Patients with cancer are at high risk for severe courses of COVID-19. Based on (pre-)clinical data suggesting a potential protective effect due to the immunomodulating properties of azithromycin, we have initiated a prospective randomized trial. Methods This randomized, single-ce...

Descrición completa

Detalles Bibliográficos

Principais autores:	Maximilian J. Mair, Agnieszka Maj-Hes, Alina Nussbaumer-Pröll, Rainer Puhr, Agnieszka Christenheit, Marlene Troch, Hannah C. Puhr, Angelika M. Starzer, Ariane Steindl, Sabine Eberl, Helmuth Haslacher, Thomas Perkmann, Christoph Minichsdorfer, Gerald W. Prager, Wolfgang W. Lamm, Anna S. Berghoff, Barbara Kiesewetter, Markus Zeitlinger, Matthias Preusser, Markus Raderer
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2023-02-01
Series:	Infectious Agents and Cancer
Assuntos:	COVID-19 SARS-CoV-2 Azithromycin Prophylactic treatment Oncology
Acceso en liña:	https://doi.org/10.1186/s13027-023-00487-x
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!